TY - JOUR
T1 - Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
AU - Boel, Anne
AU - Molto, Anna
AU - van der Heijde, Desiree
AU - Ciurea, Adrian
AU - Dougados, Maxime
AU - Gensler, Lianne S.
AU - Santos, Maria-Jose
AU - De Miguel, Eugenio
AU - Poddubnyy, Denis
AU - Rudwaleit, Martin
AU - van Tubergen, Astrid
AU - van Gaalen, Floris A.
AU - Ramiro, Sofia
N1 - Funding Information:
Competing interests aM reports grants and speaker/consultancy fees from abbVie, Pfizer, BMs, UCB and Merck, outside the submitted work; DvdH reports speaker/consultancy fees from abbVie, amgen, astellas, astraZeneca, BMs, Boehringer ingelheim, Celgene, Daiichi, eli-lilly, Galapagos, Gilead, Glaxo-smith- Kline, Janssen, Merck, novartis, Pfizer, Regeneron, Roche, sanofi, Takeda and UCB outside the submitted work and is the Director of imaging Rheumatology bv.; eDM reports grants and speaker/consultancy fees from abbVie, BMs, MsD, novartis, Pfizer, Roche and UCB outside the submitted work; DP reports grants and speaker/ consultancy fees from abbVie, MsD, novartis and Pfizer and speaker/consultancy fees from BMs, lilly, Roche, UCB and Celgene outside the submitted work; MR reports speaker/consultancy fees from abbVie, BMs, Celgene, Chugai, eli-lily, Janssen, MsD, novartis, Pfizer and UCB outside the submitted work; avT reports grants from Pfizer, abbVie, UCB and Biogen and grants and speaker/consultancy fees from novartis outside the submitted work; FavG reports grants from MsD, novartis, abbVie, the Dutch arthritis society, stichting Vrienden van sole Mio, UCB and Pfizer outside the submitted work; sR reports speaker/consultancy fees from abbVie, eli-lilly, novartis and sanofi and grants and speaker/consultancy fees from MsD outside the submitted work. aB, aC, MD, lG and MJs have nothing to disclose. GesPiC has been financially supported by the German Federal Ministry of education and Research (Bundesministerium für Bildung und Forschung—BMBF), as part of the German competence network in rheumatology (Kompetenznetz Rheuma). as funding by BMBF was reduced according to schedule in 2005 and stopped in 2007, complementary financial support has been obtained also from abbott/abbvie, amgen, Centocor, schering-Plough and Wyeth. since 2010 GesPiC is supported by abbvie, additional support has been obtained also from arthroMark (grants number FKZ 01eC1401a) and MeTaRTHROs (grant number FKZ 01eC1407a) projects funded by BMBF.
Publisher Copyright:
© Author(s) (or their employer(s)) 2019.
PY - 2019/11
Y1 - 2019/11
N2 - Background Patients with spondyloarthritis with radiographic sacroiliitis are traditionally classified according to the modified New York (mNY) criteria as ankylosing spondylitis (AS) and more recently according to the Assessment of SpondyloArthritis international Society (ASAS) criteria as radiographic axial spondyloarthritis (r-axSpA).Objective To investigate the agreement between the mNY criteria for AS and the ASAS criteria for r-axSpA and reasons for disagreement.Methods Patients with back pain >= 3 months diagnosed as axSpA with radiographic sacroiliitis (mNY radiographic criterion) were selected from eight cohorts (ASAS, Esperanza, GESPIC, OASIS, Reuma.pt, SCQM, SPACE, UCSF). Subsequently, we calculated the percentage of patients who fulfilled the ASAS r-axSpA criteria within the group of patients who fulfilled the mNY criteria and vice versa in six cohorts with complete information.Results Of the 3882 patients fulfilling the mNY criteria, 93% also fulfilled the ASAS r-axSpA criteria. Inversely, of the 3434 patients fulfilling the ASAS r-axSpA criteria, 96% also fulfilled the mNY criteria. The main cause for discrepancy between the two criteria sets was the reported age at onset of back pain.Conclusion Almost all patients with axSpA with radiographic sacroiliitis fulfil both ASAS and mNY criteria, which supports the interchangeable use of the terms AS and r-axSpA.
AB - Background Patients with spondyloarthritis with radiographic sacroiliitis are traditionally classified according to the modified New York (mNY) criteria as ankylosing spondylitis (AS) and more recently according to the Assessment of SpondyloArthritis international Society (ASAS) criteria as radiographic axial spondyloarthritis (r-axSpA).Objective To investigate the agreement between the mNY criteria for AS and the ASAS criteria for r-axSpA and reasons for disagreement.Methods Patients with back pain >= 3 months diagnosed as axSpA with radiographic sacroiliitis (mNY radiographic criterion) were selected from eight cohorts (ASAS, Esperanza, GESPIC, OASIS, Reuma.pt, SCQM, SPACE, UCSF). Subsequently, we calculated the percentage of patients who fulfilled the ASAS r-axSpA criteria within the group of patients who fulfilled the mNY criteria and vice versa in six cohorts with complete information.Results Of the 3882 patients fulfilling the mNY criteria, 93% also fulfilled the ASAS r-axSpA criteria. Inversely, of the 3434 patients fulfilling the ASAS r-axSpA criteria, 96% also fulfilled the mNY criteria. The main cause for discrepancy between the two criteria sets was the reported age at onset of back pain.Conclusion Almost all patients with axSpA with radiographic sacroiliitis fulfil both ASAS and mNY criteria, which supports the interchangeable use of the terms AS and r-axSpA.
KW - INFLAMMATORY BACK-PAIN
KW - ANKYLOSING-SPONDYLITIS
KW - CLASSIFICATION CRITERIA
KW - SEVERITY
U2 - 10.1136/annrheumdis-2019-215707
DO - 10.1136/annrheumdis-2019-215707
M3 - Article
SN - 0003-4967
VL - 78
SP - 1545
EP - 1549
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 11
ER -